ペプチド代謝障害治療薬の世界市場（～2026年）

• 英文タイトル：Global Peptide Based Metabolic Disorders Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04207 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料はペプチド代謝障害治療薬のグローバル市場について調査・分析したレポートです。種類別（エクセナチド、リラグルチド、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ペプチド代謝障害治療薬の競争状況、市場シェア ・世界のペプチド代謝障害治療薬市場：種類別市場規模 2015年-2020年（エクセナチド、リラグルチド、その他） ・世界のペプチド代謝障害治療薬市場：種類別市場規模予測 2021年-2026年（エクセナチド、リラグルチド、その他） ・世界のペプチド代謝障害治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界のペプチド代謝障害治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米のペプチド代謝障害治療薬市場分析：米国、カナダ ・ヨーロッパのペプチド代謝障害治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのペプチド代謝障害治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のペプチド代謝障害治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのペプチド代謝障害治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Ingro Finanz (Bachem)、Eli Lilly、Ipsen、Merck、Novo Nordisk、PolyPeptide Group、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability.
North America is expected to dominate the global market in terms of higher market share.

Market Analysis and Insights: Global Peptide Based Metabolic Disorders Therapeutics Market
The global Peptide Based Metabolic Disorders Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Peptide Based Metabolic Disorders Therapeutics Scope and Market Size
Peptide Based Metabolic Disorders Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Peptide Based Metabolic Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AstraZeneca
Ingro Finanz (Bachem)
Eli Lilly
Ipsen
Merck
Novo Nordisk
PolyPeptide Group
Teva Pharmaceutical

Market segment by Type, the product can be split into
Exenatide
Liraglutide
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Peptide Based Metabolic Disorders Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Exenatide
1.4.3 Liraglutide
1.4.4 Others
1.5 Market by Application
1.5.1 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Perspective (2015-2026)
2.2 Global Peptide Based Metabolic Disorders Therapeutics Growth Trends by Regions
2.2.1 Peptide Based Metabolic Disorders Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Peptide Based Metabolic Disorders Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Peptide Based Metabolic Disorders Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Peptide Based Metabolic Disorders Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Market Size
3.1.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio
3.2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Peptide Based Metabolic Disorders Therapeutics Revenue in 2019
3.3 Peptide Based Metabolic Disorders Therapeutics Key Players Head office and Area Served
3.4 Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service
3.5 Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
5.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size (2015-2020)
6.2 Peptide Based Metabolic Disorders Therapeutics Key Players in North America (2019-2020)
6.3 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
6.4 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size (2015-2020)
7.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
7.4 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Peptide Based Metabolic Disorders Therapeutics Market Size (2015-2020)
8.2 Peptide Based Metabolic Disorders Therapeutics Key Players in China (2019-2020)
8.3 China Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
8.4 China Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Peptide Based Metabolic Disorders Therapeutics Market Size (2015-2020)
9.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
9.4 Japan Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size (2015-2020)
10.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Peptide Based Metabolic Disorders Therapeutics Market Size (2015-2020)
11.2 Peptide Based Metabolic Disorders Therapeutics Key Players in India (2019-2020)
11.3 India Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
11.4 India Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size (2015-2020)
12.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Introduction
13.1.4 AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Ingro Finanz (Bachem)
13.2.1 Ingro Finanz (Bachem) Company Details
13.2.2 Ingro Finanz (Bachem) Business Overview
13.2.3 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Introduction
13.2.4 Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020)
13.2.5 Ingro Finanz (Bachem) Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Introduction
13.3.4 Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Ipsen
13.4.1 Ipsen Company Details
13.4.2 Ipsen Business Overview
13.4.3 Ipsen Peptide Based Metabolic Disorders Therapeutics Introduction
13.4.4 Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020)
13.4.5 Ipsen Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Peptide Based Metabolic Disorders Therapeutics Introduction
13.5.4 Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Novo Nordisk
13.6.1 Novo Nordisk Company Details
13.6.2 Novo Nordisk Business Overview
13.6.3 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Introduction
13.6.4 Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020)
13.6.5 Novo Nordisk Recent Development
13.7 PolyPeptide Group
13.7.1 PolyPeptide Group Company Details
13.7.2 PolyPeptide Group Business Overview
13.7.3 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Introduction
13.7.4 PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020)
13.7.5 PolyPeptide Group Recent Development
13.8 Teva Pharmaceutical
13.8.1 Teva Pharmaceutical Company Details
13.8.2 Teva Pharmaceutical Business Overview
13.8.3 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Introduction
13.8.4 Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020)
13.8.5 Teva Pharmaceutical Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Peptide Based Metabolic Disorders Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Peptide Based Metabolic Disorders Therapeutics Revenue
Table 3. Ranking of Global Top Peptide Based Metabolic Disorders Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Exenatide
Table 6. Key Players of Liraglutide
Table 7. Key Players of Others
Table 8. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Peptide Based Metabolic Disorders Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Peptide Based Metabolic Disorders Therapeutics Players
Table 19. Global Peptide Based Metabolic Disorders Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2019)
Table 22. Global Peptide Based Metabolic Disorders Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service
Table 25. Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Peptide Based Metabolic Disorders Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Peptide Based Metabolic Disorders Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Peptide Based Metabolic Disorders Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Peptide Based Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Peptide Based Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 35. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 37. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Peptide Based Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Peptide Based Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 41. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Peptide Based Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Peptide Based Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 47. China Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 49. China Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Peptide Based Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Peptide Based Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 53. Japan Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Peptide Based Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Peptide Based Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Peptide Based Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Peptide Based Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 65. India Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 67. India Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Peptide Based Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Peptide Based Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 71. Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 75. AstraZeneca Company Details
Table 76. AstraZeneca Business Overview
Table 77. AstraZeneca Product
Table 78. AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 79. AstraZeneca Recent Development
Table 80. Ingro Finanz (Bachem) Company Details
Table 81. Ingro Finanz (Bachem) Business Overview
Table 82. Ingro Finanz (Bachem) Product
Table 83. Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 84. Ingro Finanz (Bachem) Recent Development
Table 85. Eli Lilly Company Details
Table 86. Eli Lilly Business Overview
Table 87. Eli Lilly Product
Table 88. Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 89. Eli Lilly Recent Development
Table 90. Ipsen Company Details
Table 91. Ipsen Business Overview
Table 92. Ipsen Product
Table 93. Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 94. Ipsen Recent Development
Table 95. Merck Company Details
Table 96. Merck Business Overview
Table 97. Merck Product
Table 98. Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 99. Merck Recent Development
Table 100. Novo Nordisk Company Details
Table 101. Novo Nordisk Business Overview
Table 102. Novo Nordisk Product
Table 103. Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 104. Novo Nordisk Recent Development
Table 105. PolyPeptide Group Company Details
Table 106. PolyPeptide Group Business Overview
Table 107. PolyPeptide Group Product
Table 108. PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 109. PolyPeptide Group Recent Development
Table 110. Teva Pharmaceutical Business Overview
Table 111. Teva Pharmaceutical Product
Table 112. Teva Pharmaceutical Company Details
Table 113. Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 114. Teva Pharmaceutical Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Exenatide Features
Figure 3. Liraglutide Features
Figure 4. Others Features
Figure 5. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Peptide Based Metabolic Disorders Therapeutics Report Years Considered
Figure 10. Global Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players in 2019
Figure 15. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue in 2019
Figure 17. North America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

---